Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
Key facts
- Who runs it
- Yueyue Li
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 508 people enrolled
- Started
- 1 Nov 2025
- Ended
- 27 Dec 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- 7-day triple therapy
- 14-day dual therapy
- Record updated
- 12 January 2026
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- patients aged 18-70 years
- patients with H. pylori infection confirmed by 13C/14C-urea breath test or rapid urease test
- patients with no history of H. pylori eradication therapy
Who cannot take part
- patients with severe underlying diseases, such as hepatic insufficiency, renal insufficiency, immunosuppression, malignant tumors, and coronary heart disease
- patients with active gastrointestinal bleeding
- patients with a history of upper gastrointestinal surgery
- patients allergic to treatment drugs
- patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitors within 2 weeks
- patients with other behaviors that may increase the risk of disease, such as alcohol and drug abuse
- patients who were pregnant or lactating or unwilling to take contraceptive measures during the trial
- incomplete data
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
With the increasing prevalence of antibiotic resistance, the clinical efficacy of conventional 7-day triple therapy for Helicobacter pylori eradication has been substantially diminished. However, the efficacy and safety of a 7-day triple regimen based on amoxicillin and tetracycline warrant further investigation. This retrospective study was designed to compare the efficacy and safety of a 7-day triple therapy based on amoxicillin and tetracycline combination versus the standard 14-day high-dose dual therapy for H. pylori infection. Data on therapies for H. pylori eradication were extracted between January 2023 and October 2025 at Qilu Hospital of Shandong University. Two regimens were compared based on 1:3 propensity score matching: 7-day triple therapy (vonoprazan 20 mg twice daily, amoxicillin 1000 mg twice daily, and tetracycline 500 mg four times daily) and 14-day high-dose dual therapy (vonoprazan 20 mg twice daily and amoxicillin 1000 mg three times daily). Eradication rates and incidence of adverse events were assessed.
The 2 groups in the trial
- triple therapy
Treatment: 7-day triple therapy
- dual therapy
Treatment: 14-day dual therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 12 January 2026